Fresh Tracks Therapeutics

Fresh Tracks Therapeutics, formerly known as Brickell Biotech, is a clinical-stage pharmaceutical company. The company is engaged in the development of prescription drugs for the treatment of autoimmune, inflammatory, and other debilitating diseases. Its products include Cialis, Taltz, Gemzar, Prozac, Cymbalta, Juvederm, Pluvicto, and Sofpironium Bromide. FRTX-02, one of its development-stage projects, is an oral DYRK1A inhibitor for patients with autoimmune diseases, which will be used in humans. FRTX-10 is the company’s leading Stimulator of Interferon Genes (STING) candidate inhibitor, blocking the palmitoylation site of STING in the cGAS-STING pathway, which is essential for STING activation. The company's next-generation small molecule kinase inhibitor platform includes compounds targeting prominent proteins such as DYRK1A, LRRK2, TTK, and CLK, with varying potency, selectivity, and blood-brain barrier permeability.